Breast cancer cells have been detected in autologous blood stem cell collections of early stage breast cancer patients, but their clinical significance is undefined. From October 1993 to August 1998, 32 consecutive Stage II breast cancer patients with 4-9-positive nodes underwent stem cell apheresis. The patients were treated with cyclophosphamide 1.75 gm/m 2 , etoposide 400 mg/m 2 and cisplatin 50 mg/m 2 daily for 3 days, followed by infusion of the autologous cells. Cytospins of cells from each apheresis collections and from an aliquot of three pooled collections were examined for cytokeratin expression using an immunocytochemical assay. The cells were considered positive for tumor if at least one cell with tumor morphology stained positively for cytokeratin. Negative aliquots were confirmed with RT-PCR. Six patients (19%) had positive collections. In total, 24 patients (75%) were disease free a median of 61 (30-86) months after transplant. Eight patients relapsed at a median of 17 (8-27) months after transplant. Four of the disease-free patients and two of the relapsed patients had positive apheresis collections. There was no significant correlation between the presence of detectable tumor cells in the graft product and outcome.
Breast cancer patients whose only known disease is in the breast and ipsilateral axillary lymph nodes at the time of definitive therapy are at greater risk of dying from metastatic disease than are patients with no axillary involvement. 1 Standard doses of adjuvant chemotherapy and hormonal therapy after first-line treatment with radiation and/or surgery has improved the outcome of breast cancer patients, but patients with 4-9-positive axillary nodes have a greater relative risk for relapse than patients with 1-3-positive nodes. 2 The additional use of adjuvant consolidative high-dose therapy with autologous hematopoietic stem cell rescue has uncertain benefit for patients with 10 or more axillary nodes involved with tumor at diagnosis. 3 Randomized prospective studies investigating the value of consolidative high-dose therapy with autologous transplant for patients with 4-9 nodes involved at diagnosis have not yet been fully reported.
The presence of micrometastatic tumor cells in the bone marrow of breast cancer patients is associated with a poorer clinical outcome. 4, 5 Poorer outcomes have also been noted following transplantation of bone marrow containing tumor cells to high-risk breast cancer patients. 6 Mobilized blood stem cells rather than stem cells harvested from the marrow have been used for autologous hematopoietic transplantation for the past decade. Higher stage breast cancer patients receiving breast tumor-contaminated nonmobilized 7 and mobilized 8 blood stem cell transplants had a poorer outcome in some studies, but not in others. 9, 10 Administration of chemotherapy and/or cytokines to mobilize stem cells to the circulation may mobilize tumor cells as well. 11 Although one study of breast cancer patients showed that collections of hematopoietic stem cells mobilized with a combination of cytokine and chemotherapy did not contain mobilized tumor cells, 12 only one apheresis collection was assayed for each patient. Often, more than one apheresis procedure is necessary to collect sufficient numbers of progenitor/stem cells for autografting, and variable levels of tumor contamination in sequential apheresis harvests have been reported. 13, 14 Whether mobilized tumor cells have different physiologic characteristics and pathologic potential compared to nonmobilized circulating breast cancer cells is unknown. The impact on outcome of the presence of detectable tumor cells in mobilized blood stem cell harvests of patients with 4-9 nodes involved who are treated with high-dose adjuvant consolidative chemotherapy and autologous blood stem cell transplants is also not known. The present analysis was designed to investigate this issue.
Patients and methods
A total of 32 patients, median age 43 years (range 32-63 years) who had completed conventional dose doxorubicincontaining adjuvant chemotherapy for Stage II breast cancer (4-9-positive axillary nodes, median 6-positive nodes), had no evidence of metastatic disease following computerized axial tomography of the head, chest, abdomen, and pelvis and had no significant comorbid conditions were included in this study. All gave written informed consent to participate in an IRB-approved high-dose therapy and transplant trial. Apheresis products studied were collected between October 1993 and December 1997. Each apheresis collection of each patient was evaluated for the presence of occult tumor cells. Frozen and thawed aliquots of each patient's three collections were pooled and evaluated for tumor cells as well. All patients received etoposide 400 mg/m 2 , cyclophosphamide 1.75 gm/m 2 , and cisplatin 50 mg/m 2 daily for 3 days, followed by infusion of their autologous hematopoietic stem cells. The patients were subsequently followed for evidence of disease relapse and for survival.
Immunocytochemical analysis
Immunocytochemical (ICC) analysis was carried out using previously published methods 15 to detect polypeptide components of structural proteins, cytokeratins (CK), comprising the epithelial cell cytoskeleton. Since epithelial cells would not be expected in a hematopoietic stem cell graft product, these peptides were used to identify breast carcinoma cells. Briefly, the ICC staining technique employed unlabeled primary antibody followed by biotinylated secondary antibody and then a universal avidin DH/biotinylated glucose oxidase H complex. The monoclonal antibodies included Cam 5.2 (Becton Dickinson, San Jose, CA, USA) to identify CK peptides 8 and 18 and MAK-6 (Ciba-Corning, Alameda, CA, USA) to identify CK peptides 8, 14, 15, 16, 18, and 19 . Cells containing these CK peptides were identified by indirectly linking the CK antibodies to the indicator enzyme, glucose oxidase nitrozolium tetra blue, which when reduced produces a purple-blue precipitate. Cytospins of replicate samples were fixed with acetone and stained using a Vector ABC/ GO kit (Burlingame, CA, USA). Positive cells included immunoreactivity of at least 70% in the cytoplasm and morphology consistent with a tumor cell, using a light microscope.
RT-PCR analysis
RT-PCR analysis was performed using previously published methods. 15 Briefly, cellular RNA was extracted using RNA-STAT-60 (Tel-Test Inc., Friendswood, TX, USA) according to the manufacturer's instructions. Human CK19 gene primer sequences reported by Datta et al 16 were used. The first amplification used the forward (A) and reverse (B) primers that produced a 1069 base pair (bp) PCR product. The A and B primers were designed to amplify a sequence from mRNA to differentiate it from the DNA sequence and pseudogene. The second amplification used A and B nested primers that produced a 745 bp product. The RT-PCR analysis was performed using the RNA PCR kit (Perkin-Elmer, Roche Molecular System Inc.), according to manufacturer's directions with minor modifications. RNA from the human mammary cell line T47D was used as the positive control. RNA extracted from normal donor apheresis samples served as the negative control. A portion of the PCR-2 amplification reaction mixture was analyzed on a slot blot using an allelespecific oligonucleotide probe (CK19E) to verify CK19 transcripts present in small quantities not evident at the gel level. The PCR results were employed primarily to confirm negativity of ICC negative events. 15 
Definition of tumor cell contamination
Apheresis samples that contained one or more ICC-positive cell in any harvest were considered positive. PCR results were not considered in the definition of positivity due to the risk of false-positive results. Apheresis samples with no ICC-positive cells and were negative by RT-PCR were considered negative for tumor cell contamination.
Results
Samples from six of the 32 patients (19%) had detectable tumor cells in at least one autologous collection. The pooled specimens from all six of these patients had ICCpositive cells; aliquots from all three apheresis specimens were negative for three patients, and the remaining three had one ICC-positive apheresis aliquot.
Eight patients have experienced tumor relapse following high-dose therapy and autologous transplantation of the studied graft products. Two of the relapses occurred among the six patients who received a positive graft product (33%) and six relapses occurred among 24 patients who had negative graft products (25%). Kaplan-Meier analysis revealed an actuarial survival of 75% at 86 months for the entire group of patients, 77% at 86 months for those with no detectable tumor in their autograft product, and 67% at 63 months for those with detectable tumor in their transfused autologous stem cells. Log-rank analysis of event-free survival with follow-up of up to 86 months (median 61 months) showed no significant differences (P ¼ 0.62) between the tumor cell negative and positive groups.
Discussion
This study evaluated the impact on clinical outcomes of breast cancer cell contamination of blood stem cell harvests in patients with Stage II, 4-9 node-positive disease undergoing consolidative high-dose therapy and blood stem cell rescue. Some prior studies of patients with metastatic breast cancer revealed a better outcome for those receiving tumor negative graft harvests, but follow-up periods were very short. 7 However, for patients with overt metastatic disease, detection of tumor cells in autologous harvests is likely a surrogate for tumor burden and outcomes, thereby 6 Preti et al reported 10.4% ICC-positive apheresis harvests in metastatic breast cancer patients. 17 Purging of these harvests by CD34 selection reduced tumor cell burden but did not significantly increase survival. Weaver et al found 8% of Stages II-III and 10% of Stage IV patient harvests had ICC-positive tumor cells for a contamination rate of 18% of Stages II-III and 24% of Stage IV patients. 14 The presence of tumor cells was not significantly associated with an increased probability of early relapse. Kasimir-Bauer et al reported 22-29% of blood stem cell harvests from patients with advanced stage breast cancer were tumor positive. 10 Higher numbers of cytokeratinpositive cells in harvests were associated with rapid progression and short overall survival following transplant. Stadtmauer et al 9 reported 22.5% of metastatic breast cancer patients had tumor-contaminated harvests as determined by ICC but this did not correlate with decreased survival post transplant. Burgess et al observed that by standard ICC techniques, 23% of blood stem cell harvests from Stages II, III and IV breast cancer patients were contaminated with tumor cells. 18 The frequency of contaminated harvests was increased using immunoenrichment techniques and the number of contaminating tumor cells was decreased by CD34 selection techniques. The clinical consequences of these observations were not reported. In a randomized study of transplantation of CD34+ selected vs unselected blood stem cell harvests, Charbannon et al observed by ICC that 8/24 (19%) collections were contaminated with tumor. 19 Solano et al 8 reported that 27.4% of apheresis samples from patients with Stages II and III breast cancer and 10 or more positive axillary nodes were contaminated with ICC detectable tumor cells. The presence of such cells was associated with a higher incidence of disease relapse and shorter survival post-transplant. Slade et al noted that 3/23 (13%) of blood samples from primary breast cancer patients with no evidence of distant metastases were tumor positive using a PCR technique. 20 PCR technology is generally more sensitive than ICC techniques and bone marrow is more likely to be contaminated than blood.
Overall, there is a slight trend toward increased contamination of blood stem cell harvests with increasing disease stage. The discrepancy between studies is likely based to some degree on the techniques employed, especially as regards sensitivity. The greater the sensitivity the greater the proportion of positive blood stem cell harvests detected. In the heterogeneous group of 10 studies using routine techniques reviewed above (including the current study), overall 1877% of mostly Stages II-III patient harvests appeared to be contaminated with tumor cells.
The sensitivity of the ICC detection method used in this study has been estimated at one in 10 4 -10 5 cells. 15 Thus, some of the apheresis aliquots that tested negative could actually have been positive if the tumor cell content was less than one per hundred thousand cells. RT-PCR detection was only employed to confirm the negativity of ICC negative samples because of concerns over false-positive results. 15 Clearly, the frequency of tumor cells observed was low. This suggests that mobilized and/or circulating tumor cells are rare, potentially sporadic emigrants from the marrow or other sites. The ability to detect such cells is therefore highly influenced by Poisson statistical considerations.
The observation that the ICC negative mobilized blood stem cell harvests were PCR negative indicates that tumor cells were infrequent, although this result was likely influenced by the limited number of cells sampled. Even so, the frequency of patients with tumor-positive apheresis harvests in this study (19%) is essentially identical to a prior multicenter study (also 19%). 19 Although firm conclusions cannot be drawn from this small study, the presence of tumor cells in infused autograft products did not appear to affect progression-free survival in the patients studied. Other investigators have noted the presence of tumor cells in the marrow of Stages II-IIIA breast cancer patients with 10 or more positive nodes has affected outcome, 6 although Kruger et al 21 noted no difference in Kaplan-Meier survival curves between marrow apheresis positive and negative patients. Whether mobilized tumor cells have different pathogenicity as compared to tumor cells in the marrow or nonmobilized circulating tumor cells is not known, but this study with a relatively long follow-up period suggests that reinfused and presumably mobilized tumor cells are not associated with a significantly poorer outcome. This hints at differences in the biological properties of tumor cells in bone marrow vs mobilized into blood.
Although there were no significant differences in the outcomes of patients in this study, patients who received tumor-positive harvests had a numerically lower diseasefree survival. To determine if this is clinically relevant, as opposed to a statistical fluctuation, would require a very large study. Such a study is unlikely to be performed in the near future. Consequently, the impact on outcomes of the detection of occasional rare tumor cells in apheresis harvests of mobilized blood stem cells should not be a major concern, but rather a topic of additional investigation in a much larger number of patients.
